



Off-Label Use (Important)

Memantine (Namenda) is not FDA-approved for autism, and using it for ASD is considered off-label. The research on memantine in autism is mixed overall, and benefit appears more likely in a specific subset of patients with a particular clinical pattern, which is why FHW uses a structured screening and tracking approach rather than prescribing it broadly. The FDA-approved package insert also notes that safety and effectiveness in pediatric patients have not been established, which is why this protocol requires close monitoring, frequent follow-up, and clear stop/continue decision points.